Showing Results for
- Academic Journals (12)
Search Results
- 12
Academic Journals
- 12
- Search Terms:
- 1From: Psychopharmacology. (Vol. 218, Issue 4) Peer-ReviewedRationale Most individuals can accurately assess the risks and rewards associated with choice alternatives and decide accordingly; however, drug users often display maladaptive decision-making, such that choices are...
- 2From: Psychopharmacology. (Vol. 218, Issue 4) Peer-ReviewedRationale Depression and anxiety are common symptoms in Parkinson's disease for which there are no optimal treatments. Sarizotan, an agonist at serotonin receptors and partial agonist at dopamine [D.sub.2]-like...
- 3From: Psychopharmacology. (Vol. 218, Issue 4) Peer-ReviewedRational and objectives Neuropeptide Y (NPY), an orexigenic peptide that is released during periods of food restriction, has been shown to have a significant modulatory impact on drug-related behaviors. We have...
- 4From: Psychopharmacology. (Vol. 218, Issue 4) Peer-ReviewedRationale Numerous neuroimaging studies have demonstrated lower neural tissue density in chronic cocaine users, which may be linked to cognitive dysfunction. Objectives The goal of this study was to determine whether...
- 5From: Psychopharmacology. (Vol. 218, Issue 4) Peer-ReviewedRationale Electrical stimulation of the dorsal periaqueductal gray (dPAG) evokes escape, a defensive response associated with panic attacks. Stimulation of 5-HT1A or 5-HT2A receptors in this midbrain area equally...
- 6From: Psychopharmacology. (Vol. 218, Issue 4) Peer-ReviewedRationale Preclinical and clinical research suggests that the endogenous cannabinoid system is involved in cognitive impairments related to schizophrenia. In particular, the deficient generation of mismatch negativity...
- 7From: Psychopharmacology. (Vol. 218, Issue 4) Peer-ReviewedIntroduction The a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor potentiator Org 26576 represents an interesting pharmacological tool to evaluate the utility of glutamatergic enhancement towards the...
- 8From: Psychopharmacology. (Vol. 218, Issue 4) Peer-ReviewedRationale [alpha]7 nicotinic acetylcholine receptor (nAChR) agonists are proposed as candidate agents for the adjunctive treatment of cognitive deficits associated with schizophrenia. Despite the pursuit of such an...
- 9From: Psychopharmacology. (Vol. 218, Issue 4) Peer-ReviewedRationale Repeated administrations of the D2/D3 agonist quinpirole (QNP) to rats elicit an antieconomical pattern of drinking called "contrafreeloading" (CFL), a putative model of compulsive-like behavior. Objectives...
- 10From: Psychopharmacology. (Vol. 218, Issue 4) Peer-ReviewedRationale Nicotine has been shown to improve both memory and attention when assessed through speeded motor responses. Since very few studies have assessed effects of nicotine on visual attention using measures that are...
- 11From: Psychopharmacology. (Vol. 218, Issue 4) Peer-ReviewedRationale This dose-effect study extends previous observations showing that psilocybin can occasion mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. Objectives This...
- 12From: Psychopharmacology. (Vol. 218, Issue 4) Peer-ReviewedRationale There is increased interest in elucidating the range of symptoms of schizophrenia and their response to treatment with medications. Particularly negative and cognitive symptoms are often resistant to the...